Abbott Laboratories [NYSE: ABT] gained 0.64% or 0.72 points to close at $113.36 with a heavy trading volume of 6806171 shares.
The daily chart for ABT points out that the company has recorded 2.57% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 5.96M shares, ABT reached to a volume of 6806171 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Abbott Laboratories [ABT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $126.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.78. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 19, 2024. The new note on the price target was released on July 30, 2024, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $121, while Goldman analysts kept a Buy rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 1.69, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 4.84. The Price to Book ratio for the last quarter was 5.02, with the Price to Cash per share for the same quarter was set at 4.15. Price to Free Cash Flow for ABT in the course of the last twelve months was 34.88 with Quick ratio for the last quarter at 1.18.
Trading performance analysis for ABT stock
Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.57. With this latest performance, ABT shares dropped by -0.44% in over the last four-week period, additionally plugging by 2.57% over the last 6 months – not to mention a rise of 17.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 49.90, with the RSI for the last a single of trading hit 48.22, and the three-weeks RSI is set at 51.86 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 112.37, while it was recorded at 113.09 for the last single week of trading, and 110.11 for the last 200 days.
Abbott Laboratories [ABT]: A deeper dive into fundamental analysis
Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.18 and a Current Ratio set at 1.68.
Abbott Laboratories [ABT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Abbott Laboratories posted 1.14/share EPS, while the average EPS was predicted by analysts to be reported at 1.1/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.04. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 8.24%.
An analysis of Institutional ownership at Abbott Laboratories [ABT]
There are presently around $79.57%, or 79.99%% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 166.35 million shares, which is approximately 9.5932%. BLACKROCK INC., holding 131.13 million shares of the stock with an approximate value of $$13.63 billion in ABT stocks shares; and BLACKROCK INC., currently with $$7.73 billion in ABT stock with ownership which is approximately 4.2903%.
